| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8629185 | ALLERGAN INC | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
Jul, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398707 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(7 months from now) | |
| US8673341 | ALLERGAN INC | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb, 2025
(1 year, 4 months from now) | |
| US9149428 | ALLERGAN INC | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(3 years from now) | |
| US10441543 | ALLERGAN INC | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(3 years from now) | |
| US8206737 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(3 years from now) | |
| US7799336 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2029
(5 years from now) | |
| US9980974 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) | |
| US9492316 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(11 years from now) | |
Durysta is owned by Allergan Inc.
Durysta contains Bimatoprost.
Durysta has a total of 9 drug patents out of which 0 drug patents have expired.
Durysta was authorised for market use on 04 March, 2020.
Durysta is available in implant;ophthalmic dosage forms.
Durysta can be used as reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant.
The generics of Durysta are possible to be released after 31 October, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 4, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
DURYSTA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic